Non-Invasive Prenatal Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

Non-invasive prenatal testing market size is set to record a 12.4% CAGR during 2024-2032 propelled by a surging demand for early and precise prenatal screening.

Non-invasive prenatal testing (NIPT) stands out as a secure and dependable method for identifying genetic anomalies in fetuses, such as Down syndrome, all while posing minimal risks to both mother and child. As awareness about the advantages of early genetic screening amplifies, the demand for these products will also rise.

Advancements in next-generation sequencing and bioinformatics are bolstering the accuracy and efficiency of NIPT, rendering it increasingly appealing to expectant parents. With enhanced access to prenatal care and rising disposable incomes in emerging markets, there is a notable uptick in product adoption, as more individuals can afford and are actively seeking advanced prenatal screening services. For example, in March 2024, BillionToOne launched 'BabyPeek', a novel prenatal genetic test, in the U.S.

The overall industry is divided into product, technology, application, end-use, and region.

Based on technology, the non-invasive prenatal testing market size from the PCR segment is expected to generate notable revenue by 2032 due to its pivotal role in enhancing the accuracy and reliability of genetic screening. PCR technology adeptly amplifies and analyzes minute quantities of fetal DNA found in maternal blood, facilitating the detection of genetic anomalies with heightened sensitivity and specificity.

NIPT market from the microdeletion detection application segment is projected to observe a robust CAGR during 2024 - 2032. This is owing to its ability to identify subtle genetic abnormalities that are not always detected by traditional screening methods. Microdeletions involve the loss of small segments of chromosomes, which can lead to various genetic disorders.

Asia Pacific non-invasive prenatal testing industry size will grow substantially between 2024 and 2032. This growth is fueled by heightened awareness of advanced prenatal screening technologies, increasing disposable incomes, and an evolving healthcare infrastructure. Moreover, advancements in genetic testing, broader access to healthcare, a rising prevalence of genetic disorders, and a growing emphasis on timely and accurate prenatal care bolster the region's market development.

Product Code: 10245

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 High incidence rate of genetic disorders
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Growing demand for early and non-invasive diagnosis
  - 3.2.1.4 Shift toward non-invasive testing
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Ethical considerations and cost of the test
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technology landscape
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Epidemiology scenario
3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables and reagents
5.3 Instruments
5.4 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 NGS
6.3 PCR
6.4 cfDNA
6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Trisomy detection
7.3 Microdeletion detection
7.4 Sex chromosome aneuploidy detection
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Diagnostic laboratories
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Agilent Technologies, Inc.
10.2 BGI
10.3 Centogene N.V.
10.4 Eurofins LifeCodexx GmbH
10.5 F. Hoffmann-La Roche Ltd.
10.6 IGENOMIX
10.7 Illumina, Inc.
10.8 Labcorp
10.9 MedGenome Labs Ltd.
10.10 Myriad Women's Health, Inc.
10.11 Natera, Inc.
10.12 Pacific Biosciences
10.13 PerkinElmer Inc.
10.14 Progenity, Inc.
10.15 Quest Diagnostics, Inc